Adaptive Biotechnologies Announces Collaboration with Takeda for Minimal Residual Disease Measures

clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.